High failure rates in clinical trials remain a primary concern for the pharmaceutical industry, and the Organoids On Chips Model Market offers a strategic solution. Many drugs that perform well in preclinical animal models fail to translate effectively in human trials due to physiological differences. Organoid-on-chip models bridge this gap by providing a human-centric testing environment that...